UCR identifies new tool to kill mosquitoes
Scientists have finally found malaria’s Achilles’ heel, a neurotoxin that isn’t harmful to any living thing except Anopheles mosquitoes that spread malaria.
Nearly half the world’s population lives in areas vulnerable to malaria which kills roughly 450,000 people per year, most of them children and pregnant women. Progress fighting the disease is threatened as Anopheles develop resistance to chemical insecticides used to control them. There is also great concern about toxic side effects of the chemicals.
About 30 years ago, scientists identified a strain of bacteria that kills Anopheles. Since the bacteria’s method of attack was not understood, it couldn’t be replicated or used as an alternative to chemical insecticides — until now.
An international team led by Sarjeet Gill, distinguished professor of molecular, cell and systems biology at UC Riverside, has identified a neurotoxin produced by the bacteria, and determined how it kills Anopheles. Their work is detailed in a paper published today in Nature Communications.
It took Gill and his team 10 years to achieve a breakthrough in their quest to understand the bacteria, and Gill attributes the success to modern gene sequencing techniques. They hit the bacteria with radiation, creating mutant bacterial strains that could not produce the toxin. By comparing the nontoxic strain to the one that kills Anopheles, they found proteins in the bacteria that are the keys to toxin production.
“Identifying the mechanisms by which the bacteria targets Anopheles has not been easy,” Gill said. “We were excited not only to find the neurotoxin, called PMP1, but also several proteins that likely protect PMP1 as it’s being absorbed in the mosquito’s gut.”
Many neurotoxins generally target vertebrates, and PMP1 bears 30 percent chemical similarity to botulinum or tetanus, both highly toxic to humans. Because the neurotoxin does not affect humans, vertebrates, fish, or even other insects, Gill believes the bacteria that produce PMP1 likely co-evolved along with Anopheles mosquitoes.
“It was surprising for us that PMP1 is not toxic to mice even by injection,” Gill said.
Members of Gill’s team include postdoctoral scholars Estefania Contreras, Jianwu Chen, Harpal Dhillon, and Nadia Qureshi as well as graduate student Swati Chawla from UC Riverside, Geoffrey Masuyer and Pål Stenmark from Stockholm University and Han Lim Lee from the Institute for Medical Research in Malaysia. Their work was funded by the U.S. National Institutes of Health.
The team has applied for a patent on this discovery, and now hopes to find partners that will help them develop their bacteria-based Anopheles insecticide. These findings also open the door to new avenues of research on additional environmentally friendly insecticides.
“There is a high likelihood that if PMP1 evolved to kill the Anopheles mosquito, there are other toxins that can kill other disease-spreading pests,” Gill said. “This could just be the start of a new way to prevent hundreds of thousands from getting sick and dying every year.”
Learn more: Controlling deadly malaria without chemicals
The Latest on: Malaria
via Google News
The Latest on: Malaria
- Hong Kong investigates fatal malaria case following 30 imported infectionson August 4, 2022 at 8:56 pm
Hong Kong’s Centre for Health Protection (CHP) has launched an investigation into a fatal malaria case after the city recorded 30 imported cases since July. A 52 year old, who died while completing ...
- Quantifying spatial heterogeneity of malaria in the endemic Papua region of Indonesia: Analysis of epidemiological surveillance dataon August 4, 2022 at 6:46 pm
This study suggests that areas with varying levels of transmission-intensities exhibited distinct characteristics. Malaria was distributed in a markedly disproportionate manner throughout the region, ...
- Lab-engineered antibody appears to protect from malaria, study showson August 4, 2022 at 11:41 am
U.S. government researchers found that a lab-engineered antibody protected most participants from infection with the malaria parasite -- including all of those who received a higher dose of the ...
- Monoclonal Antibody Studied for Prevention of Malariaon August 4, 2022 at 11:09 am
A next-generation antimalarial monoclonal antibody, L9LS, administered intravenously or subcutaneously, shows protective efficacy against controlled malaria infection, without evident safety concerns, ...
- Monoclonal antibody shown to be effective against malaria for up to six monthson August 4, 2022 at 7:30 am
A large team of researchers affiliated with a host of institutions across the U.S. has developed a monoclonal antibody proven to be effective against malaria, perhaps for as long as six months, in a ...
- Monoclonal Antibody Might Help Prevent Malariaon August 4, 2022 at 4:38 am
Seder and his colleagues have been developing a different approach to prevention: a monoclonal antibody that recognizes a protein on the sporozoite's surface, with the aim of keep ...
- Antibody to prevent malaria infection aces first human trialson August 3, 2022 at 4:38 pm
Promising results have been published from a Phase 1 human trial testing a novel antibody treatment designed to prevent malaria infection. Almost every volunteer was protected from infection after ...
- High Hopes for New Monoclonal Antibody for Malariaon August 3, 2022 at 2:33 pm
Just one dose of the antimalarial antibody L9LS conferred protection to 15 out of 17 recipients challenged with controlled human malaria infection. In contrast, the six controls not receiving the ...
- A shot of immune proteins may protect against malaria for monthson August 3, 2022 at 2:09 pm
A monoclonal antibody for malaria passed an early hurdle and now will be tested in children in Africa, who are most at risk of dying from the disease.
- Monoclonal antibody treatment for malaria shows encouraging resultson August 3, 2022 at 2:00 pm
An experimental antibody treatment prevented malaria in the majority of participants in a small but important new study, providing a measure of hope in the effort to lower the burden of the disease ...
via Bing News